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Summary  18 
Lassa virus (LASV) small zinc-finger protein (Z), which contains two L-domain motifs, 19 
plays a central role in virus budding. Here, we report that coexpression of glycoprotein 20 
(GPC) alters the requirements of cholesterol, but not the L-domains and host factor, 21 
Tsg101, for Z-induced virus-like particle (VLP) production. Especially, the cholesterol 22 
requirement for VLP production was cell type-dependent. In addition, GPC was 23 
important for colocalization of Z with CD63, a late endosome marker. We also found 24 
that the N-terminal region (amino acids 3 – 10) of Z was critical for its myristoylation 25 
and VLP production. These findings will contribute to our understanding of LASV 26 




Arenaviruses are bisegmented RNA viruses, and both segments encode two viral 29 
proteins—nucleoprotein (NP) and glycoprotein (GPC) are encoded by the S segment, 30 
while RNA polymerase (L) and small zinc-finger protein (Z) are encoded by the L 31 
segment (Buchmeier, 2013). Several arenaviruses cause hemorrhagic fever in humans. 32 
Lassa virus (LASV) causes Lassa fever, which has high morbidity and mortality rates. 33 
Therefore, LASV is a major health concern in West Africa, where several hundred 34 
thousand cases of infection are reported annually. 35 
All arenavirus Z proteins have the same structural properties (Urata & Yasuda, 2012). 36 
The N-terminus includes Gly at position 2 (G2). G2 of Z is known to be myristoylated 37 
and is critical for cellular membrane attachment and subsequent virion release (Perez et 38 
al., 2004; Strecker et al., 2006). The central domain includes the RING domain (zinc 39 
finger motif), which has been shown to regulate genome replication and gene 40 
transcription (Cornu & de la Torre, 2001, 2002; Cornu et al., 2004; Emonet et al., 2011; 41 
Kranzusch & Whelan, 2011; Urata & de la Torre, 2011). The C-terminus includes 42 
L-domains, which are known to regulate the virus budding process. All reported 43 
arenavirus Z proteins have been shown to play a central role in virus budding (Perez et 44 
al., 2003; Strecker et al., 2003; Urata & de la Torre, 2011; Urata et al., 2009; Urata et al., 45 
2006). Therefore, Z is considered to be an arenavirus matrix protein. The short amino 46 
acid motifs, PT/SAP, PPxY, YPXnL, and FPIV, have been reported as consensus 47 
sequences of the L-domain (Bieniasz, 2006; Chen & Lamb, 2008; Freed, 2002). 48 
PT/SAP and YPXnL interact with Tsg101 and Alix/AIP1, respectively (Martin-Serrano 49 
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et al., 2003; Strack et al., 2003). These host factors are involved in the Endosomal 50 
Sorting Complex Required for Transportation (ESCRT) machinery. The PPxY motif 51 
interacts with E3 ligases of the Nedd4 family, but the role of E3 ligases in virus budding 52 
has not been determined (Martin-Serrano et al., 2005). LASV Z possesses two 53 
canonical L-domain motifs, PTAP and PPPY, at its C-terminus. Both of these motifs are 54 
important for LASV budding (Perez et al., 2003; Strecker et al., 2003). 55 
In the present study, we found that GPC, but not NP, influenced the Z-mediated VLP 56 
production efficiency in a cell type-dependent manner. We also examined the 57 
cholesterol requirement for Z- and Z+GPC-mediated VLP production in several cell 58 
lines, and found that the cholesterol requirement for VLP production is also cell 59 
type-dependent. In addition, we showed that GPC expression is important for 60 
colocalization of Z with CD63, which is a late endosome marker. Finally, we examined 61 
the involvement of other regions of Z than G2 and L-domains in Lassa VLP production, 62 
and found that the region from amino acids 3 – 10 is important for myristoylation of Z 63 
and subsequent VLP production. These findings contribute to our understanding of 64 
LASV Z-mediated VLP production, especially the trans (GPC and cellular cholesterol) 65 





Effects of GPC and NP on LASV Z-mediated VLP production. To examine the 69 
effects of GPC and/or NP on LASV Z-mediated VLP production, the expression 70 
plasmid for LASV Z, pCLV-Z, was transfected into 293T cells together with expression 71 
plasmids for LASV GPC, pCLV-GPC, and/or for LASV NP, pCLV-NP-HA, and the 72 
levels of VLP production were examined as described in the Methods section. As shown 73 
in Fig. 1A, coexpression of GPC and NP did not affect the cellular expression of Z. 74 
Coexpression of GPC together with Z decreased Z-mediated VLP production (50%), 75 
while NP expression did not significantly affect Z-mediated VLP production or 76 
Z+GPC-mediated VLP production in 293T cells.  77 
Effects of cholesterol depletion on Lassa VLP production. Previously, LASV GPC 78 
was reported to redirect Z from the basolateral side to the apical side in the polarized 79 
cell line, MDCK-II (Schlie et al., 2010b). Although 293T cells are not known as a 80 
polarized cell line, it is possible that the reduction of Z-mediated VLP production by 81 
GPC in 293T cells was due to the alteration of processing or assembly/release site of 82 
VLP production in the cell. Especially, we focused on lipid rafts, which are 83 
microdomains on the cell surface that mainly consist of cholesterol and lipids (Simons 84 
& Sampaio, 2011). In fact, several viruses have been reported to utilize lipid rafts as a 85 
budding platform (Kerviel et al., 2013; Takeda et al., 2003). In addition, it has been 86 
reported that cholesterol presents on the envelope of LASV and is important for viral 87 
infectivity (Schlie et al., 2010a). To examine whether lipid rafts are involved in VLP 88 
production, we treated 293T cells with 8.7 mM methyl-beta-cyclodextrin (MβCD), 89 
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which is known to disrupt lipid rafts by chelating cholesterol, for 30 minutes prior to 90 
transfection with pCLV-Z or pCLV-Z+pCLV-GPC. MβCD treatment did not affect the 91 
intracellular expression of Z or GP2 (Fig. 1B). MβCD treatment had little effect on 92 
Z-mediated VLP production, while Z+GPC-mediated VLP production was significantly 93 
decreased by MβCD treatment (Fig. 1B). We next examined whether the effects of 94 
MβCD treatment on Z or Z+GPC VLP production are cell type-dependent. Huh-7 and 95 
Vero cells were treated with MβCD or control DMSO, and transfected with pCLV-Z or 96 
pCLV-Z+pCLV-GPC, as described in the Methods section. As GPC/GP2 could not be 97 
detected by anti-GPC/GP2 antibody in MDCK cell lysates, pCLV-GPC-FLAG was 98 
transfected instead of pCLV-GPC and anti-FLAG antibody was used to detect LASV 99 
GP2 in MDCK cells. In Huh-7 cells (Fig. 1C, left), the levels of Z and GPC expression 100 
were equivalent between DMSO and MβCD treatment groups. VLP production induced 101 
by Z was reduced upon GPC coexpression, similar to our observations in 293T cells 102 
(Fig. 1A, lanes 1 and 2). In addition, VLP production induced by Z+GPC was reduced 103 
upon MβCD treatment in Huh-7 cells, similar to our observations in 293T cells (Fig. 104 
1B), while VLP production induced by Z alone was unaffected by MβCD treatment. In 105 
Vero cells (Fig. 1C, middle), although there were modest reductions in Z and GPC 106 
expression upon MβCD treatment, both Z and Z+GPC induced VLP production were 107 
markedly reduced upon MβCD treatment compared to control DMSO treatment. In 108 
MDCK cells (Fig. 1C, right), Z and GPC expression levels were equivalent between 109 
DMSO and MβCD treatment groups, and MβCD treatment did not affect Z- or 110 
Z+GPC-mediated VLP production. In all cell lines tested, no or only modest cell 111 
toxicity was observed based on Z or GPC/GP2 expression levels in the cells.  112 
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Intracellular localization of LASV Z and GPC/GP2. Our data shown in Fig. 1B 113 
suggested that cholesterol is required for Z+GPC VLP production in 293T cells. 114 
Confocal microscopy was performed to examine whether Z and GPC are colocalized at 115 
lipid rafts as a membrane budding platform. 293T cells were transfected with 116 
pCLV-Z-FLAG, pCLV-GPC, or pCLV-Z-FLAG+pCLV-GPC and fixed at 24 hours 117 
posttransfection. Z was detected by mouse anti-FLAG monoclonal antibody and 118 
GPC/GP2 was detected by rabbit anti-GPC/GP2 polyclonal antibody. In addition, lipid 119 
rafts were detected using a Vybrant Lipid Raft labeling kit containing cholera toxin 120 
subunit B (CT-B) to specifically bind to the plasma membrane (PM) lipid raft marker, 121 
ganglioside GM1. When LASV Z was expressed alone, Z was mainly localized at the 122 
PM, but colocalization of Z and rafts was not observed (Fig. 2A). GPC/GP2 was also 123 
mainly localized at the PM, but colocalization of GPC/GP2 and lipid rafts was not 124 
detected (Fig. 2B). Although colocalization of Z and GPC/GP2 was observed at a 125 
limited point near the PM when both were expressed (Fig. 2C and D, arrows), 126 
colocalization of lipid rafts and Z/GPC/GP2 was not observed (Fig. 2D and 2E). Next, 127 
we focused on CD63, which is a late endosome marker that was previously shown to be 128 
colocalized with LASV Z in experiments using infectious LASV (Fehling et al., 2013). 129 
Z alone or Z+GPC were expressed in 293T cells, and the intracellular localization of Z 130 
was examined by laser confocal microscopy, together with that of CD63. As shown in 131 
Fig. 3, when Z was expressed alone, colocalization with CD63 was rarely detected. On 132 
the other hand, when GPC was coexpressed with Z, colocalization of CD63 and Z was 133 
observed approximately three times more frequently than Z alone (Fig. 3C). 134 
VLP production induced by LASV Z and GPC requires Tsg101 and viral 135 
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L-domain. The data shown in Fig. 1 suggested that previously reported factors required 136 
for Z-mediated VLP production may be altered by the coexpression of GPC. Previously, 137 
we and other groups reported that Lassa Z-mediated VLP budding requires Tsg101, 138 
which is one of the key components of the ESCRT machinery, as a host factor (Perez et 139 
al., 2003; Urata et al., 2006). Therefore, we examined whether Tsg101 also plays an 140 
essential role in LASV Z+GPC-mediated VLP production as a host factor (Garrus et al., 141 
2001; Urata et al., 2006). 293T cells were pretreated with siRNA specific for Tsg101 142 
(siTsg101) or control siRNA (siCont) as described previously (Urata et al., 2006), and 143 
then transfected with pCLV-Z and pCLV-GPC, together with siTsg101 or siCont. At 48 144 
hours posttransfection, the VLP fraction and cell lysate were collected. Viral and 145 
cellular proteins in each fraction or lysate were separated by SDS-PAGE and then 146 
analyzed by Western blotting using the indicated antibodies (Fig. 4A). As shown in Fig. 147 
4A, Z+GPC-mediated VLP production was decreased to 40% of control by depletion of 148 
Tsg101, suggesting that Tsg101 is involved in Z+GPC-mediated VLP budding as well as 149 
Z-mediated VLP budding (Perez et al., 2003; Urata et al., 2006).  150 
We next examined whether L-domains still have an impact on LASV Z+GPC-mediated 151 
VLP production. We constructed expression plasmids for L-domain mutants of LASV Z, 152 
pCLV-Z-AAAP and pCLV-Z-PPPA, which have PTAP to AAAP or PPPY to PPPA 153 
mutation, respectively. 293T cells were transfected with pCLV-Z, pCLV-Z-AAAP, or 154 
pCLV-Z-PPPA, together with pCLV-GPC. At 48 hours posttransfection, the VLP 155 
fraction and cell lysate were collected and then analyzed by Western blotting. As shown 156 
in Fig. 4B, intracellular expression levels of Z were similar among WT and L-domain 157 
mutants. GP2 expression levels were also equivalent among cells expressing WT or 158 
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mutant Z proteins. The levels of VLP production induced by both Z L-domain mutants 159 
were markedly decreased compared to WT (74% reduction for pCLV-Z-AAAP and 85% 160 
reduction for pCLV-Z-PPPA, Fig. 4B).  161 
Identification of the region within Z critical for VLP formation. We confirmed that 162 
L-domains within Z play a critical role in Z+GPC VLP production (Fig. 4B) (Perez et 163 
al., 2003; Strecker et al., 2003). The whole RING domain in LASV Z was also reported 164 
to be important for VLP production (Wang et al., 2012). Nevertheless, functional 165 
domains other than Gly at position 2 (G2), which is known to be important for Z 166 
myristoylation and subsequent virion production, the whole RING domain, and 167 
L-domains, have not been identified. To examine the existence of as yet unknown 168 
functional domains involved in Lassa VLP production, we constructed a series of LASV 169 
Z deletion mutants (Fig. 5A), and performed VLP assay in 293T cells. As shown in Fig. 170 
5B, the mutants showed various intracellular expression levels. However, VLP 171 
production efficiencies of most mutants were similar to that of WT (Fig. 5C). Only the 172 
∆1 mutant with deletion of amino acids 3 – 10 showed a significant defect in VLP 173 
production. Although the reasons for the differences in intracellular Z expression levels 174 
of mutants are not clear, they may be related to the stabilities of the Z mutant proteins or 175 
the binding affinities of Z mutants to the anti-Z polyclonal antibody used in this study. 176 
Previously, LASV GPC was reported to form a VLP without Z expression in several 177 
mammalian cell lines, including 293T cells (Schlie et al., 2010b). Therefore, we 178 
examined whether coexpression of GPC rescued the VLP production defect of ∆1 179 
mutant in 293T cells. As shown in Fig. 5D, coexpression of GPC did not rescue this 180 
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defect. G2 of LASV Z has been reported to be important for its myristoylation and the 181 
interaction with stable signal peptide (SSP) in GPC (Capul et al., 2007). As the ∆1 182 
region is localized next to G2, we examined whether ∆1 affected the myristoylation of Z. 183 
293T cells were transfected with empty vector, pCLV-Z, pCLV-Z∆1, or pCLV-ZG2A, 184 
containing a Gly to Ala mutation at amino acid position 2, and myristoylation of each 185 
protein was examined as described in the Methods section. As shown in Fig. 5E, the 186 
expression levels of WT, ∆1, and G2A in cells were similar. WT was myristoylated, 187 
while ∆1 and G2A were not. Next, to examine whether this VLP production defect of 188 
∆1 is due to deletion of this region, two mutants were constructed. Myristoylation of 189 
HIV-1 Gag and RSV v-src at G2 were documented previously (Freed et al., 1994; 190 
Kaplan et al., 1988; Ono & Freed, 1999). Therefore, LASV Z amino acids 3 – 10 were 191 
replaced with HIV-1 Gag 3 – 10 or v-src 3 – 10 to construct pHIV-1 Gag10 LASV Z 192 
(HIV-1 Gag10) or pv-src10 LASV Z (v-src10), respectively (Fig. 5F). Both mutants 193 
showed reduced expression levels in the cells, and 48% and 42% reductions of VLP 194 
production compared to WT based on normalized VLP production, respectively (Fig. 195 
5G). The intracellular localizations of these mutant proteins were also examined. As 196 
shown in Fig. 5H, these mutants were rarely colocalized with CD63, but were localized 197 
at the plasma membrane the same as WT (Fig. 5H). 198 
Identification of the amino acid within positions 3 – 10 of Z critical for VLP 199 
production. A defect of VLP production was observed in ∆1, and replacement of LASV 200 
Z 3 – 10 to both HIV-1 Gag 3 – 10 and v-src 3 – 10 recovered this defect. To further 201 
analyze the importance of amino acids 3 – 10 of LASV Z, and to identify the amino 202 
acids critical for VLP production, three more mutants containing a linker sequence 203 
11 
 
(GGGS) were constructed (Fig. 6A). LASV Z 3 – 10 was replaced with GGGS × 2 to 204 
construct mut1 (Fig. 6A). LASV Z 3 – 6 or 7 – 10 was replaced with GGGS to construct 205 
mut2 or mut3, respectively (Fig. 6A). As mut1 showed significant reduction of 206 
intracellular expression (Fig. 6B), only mut2 and mut3 were used to examine VLP 207 
production. Both mut2 and mut3 showed lower protein expression levels compared to 208 
WT in the cells, and reduction of VLP production ratio compared to WT (65% and 54% 209 
reduction, respectively) (Fig. 6C). To examine the contribution of each amino acid to 210 
Z-mediated VLP production, single amino acid mutations were introduced into this 211 
region and VLP assay was performed. As shown in Fig. 6D, none of these amino acid 212 
mutants showed a defect in Z-mediated VLP production. As reported previously, G2A 213 
mutant showed complete abolition of VLP production due to the lack of myristoylation 214 
(Perez et al., 2004; Strecker et al., 2006). Furthermore, we introduced double lysine to 215 
alanine mutation (K4, 7A) to examine the contribution of double lysines, which may 216 
affect protein folding, on VLP production. Only modest reduction of VLP production 217 
was observed in K4, 7A mutant compared to WT, suggesting that the single and double 218 




Here, we showed that LASV GPC, but not NP, decreased Z-mediated VLP production in 221 
293T cells (Fig. 1A), and GPC also influenced the sensitivity of Z-mediated VLP 222 
production to MβCD treatment (Fig. 1B). Interestingly, the sensitivity against MβCD 223 
treatment for VLP production was cell type-dependent (Fig. 1B and 1C). Huh-7 cells 224 
showed similar results to 293T cells (Fig. 1B and 1C). Z+GPC induced VLP production 225 
was reduced upon MβCD treatment, but Z-induced VLP production was unaffected (Fig. 226 
1C, left). In Vero cells, both Z alone and Z+GPC-induced VLP production were reduced 227 
upon MβCD treatment (Fig. 1C, middle). In MDCK cells, both Z alone and 228 
Z+GPC-induced VLP production were unaffected by MβCD treatment (Fig. 1C, right). 229 
These results suggested that the cholesterol requirement for Z or Z+GPC mediated VLP 230 
production is cell type-dependent. It was reported that both GP in LASV-infected 231 
MDCK cells and GP-transfected MDCK cells exhibited the same apical surface 232 
expression pattern, suggesting that the transient GP expression distribution showed the 233 
same pattern as LASV-infected GP (Schlie et al., 2010b). 234 
Previous studies on other arenaviruses, including JUNV, Mopeia virus, Pichinde virus, 235 
and Tacaribe virus, as well as the present study indicated that other viral proteins could 236 
modulate Z-mediated VLP production and affect the efficiency of VLP production 237 
(Casabona et al., 2009; Groseth et al., 2010; Shtanko et al., 2010; Wang et al., 2012). 238 
Therefore, we propose that coexpression of GPC together with Z is necessary to mimic 239 
LASV budding. 240 
Based on the results shown in Fig. 1 indicating that cholesterol is required for 241 
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Z+GPC-mediated VLP production in 293T cells, we examined whether lipid rafts, in 242 
which cholesterol is one of the main components, on the PM act as platforms for 243 
Z+GPC budding in 293T cells. Although colocalization of Z/GPC and lipid rafts was 244 
not detected, colocalization of Z and GPC/GP2 was sometimes detected (Fig. 2). As 245 
cholesterol is involved in the virion membrane and plays a critical role in infection 246 
(Schlie et al., 2010a), and the results presented here indicating that Z or 247 
Z+GPC-mediated VLP production were reduced on MβCD treatment, but in a cell 248 
type-dependent manner, cholesterol appears to be an important trans factor for 249 
producing an infectious LASV. In addition, the observations that LASV Z and GPC are 250 
localized at detergent-soluble membrane regions in CHO-K1 cells (transfection system) 251 
and in Huh-7 cells (infection system) (Schlie et al., 2010a) and that LASV Z and GPC 252 
do not colocalize with lipid rafts (Fig. 2) indicate that these proteins are mainly 253 
localized at non-lipid rafts, detergent-soluble membrane areas. Considering these results, 254 
it is possible that once LASV Z and GPC reach the PM, they localize at non-lipid rafts, 255 
detergent-soluble membrane areas, but relocalize to the cholesterol-rich domains, lipid 256 
rafts, just before budding and incorporate cholesterol into the virion, as proposed for 257 
JUNV (Agnihothram et al., 2009). 258 
It has been shown that LASV Z colocalizes with CD63 and M6PR, both of which are 259 
late endosome markers (Fehling et al., 2013). Therefore, we examined whether LASV Z 260 
alone or LASV Z+GPC colocalized with CD63. In fact, we found that GPC relocalized 261 
Z to CD63 (Fig. 3), indicating that GPC is important to mimic Z-mediated VLP 262 
assembly and budding. 263 
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It was demonstrated that GPC expression did not alter the requirements for Tsg101 and 264 
L-domains in LASV Z and Z+GPC on VLP budding (Fig. 4A and B). These results 265 
agreed with a previous report using the LASV infection system (Strecker et al., 2003) 266 
and suggested the involvement of LASV Z L-domains in virion production. These 267 
results (Figs. 1 and 4) suggested that both Z and GPC are required to mimic Lassa virus 268 
assembly/budding using the VLP system.  269 
All arenavirus Z proteins reported to date have been shown to be matrix proteins with 270 
bona fide budding activity. To determine if there are other regions that regulate 271 
Z-mediated VLP production than G2 or L-domains, which are well characterized, we 272 
constructed a series of deletion mutants and examined VLP production. We showed that 273 
the region consisting of amino acids 3 – 10 (∆1) of LASV Z was critical for VLP 274 
production (Fig. 5A – C), and this was due to the lack of myristoylation (Fig. 5E). To 275 
examine whether LASV Z myristoylation and subsequent VLP production require 276 
specific amino acids 3 – 10 of LASV Z, these residues of the original LASV Z sequence 277 
were replaced with HIV-1 Gag (HIV-1 Gag10) or RSV v-src (v-src10). Both proteins 278 
are myristoylated at G2 (Fig. 5F) (Freed et al., 1994; Ono & Freed, 1999; Schultz et al., 279 
1985). Both mutants showed lower protein expression levels compared to WT in the 280 
cells, suggesting that amino acids 3 – 10 are at least partially required for protein 281 
expression or stability. In addition, although the VLP production ratios were reduced 282 
compared to WT, both mutants rescued VLP production, suggesting that LASV Z does 283 
not require a specific amino acid in the region comprised of amino acids 3 – 10 for VLP 284 
production (Fig. 5G). These mutants did not exhibit differences in intracellular 285 
distribution compared to WT (Fig. 5H). Next, to further explore the importance of this 3 286 
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– 10 amino acid sequence for LASV Z-mediated VLP production, we generated a 287 
mutant (mut1) in which amino acids within the ∆1 (3 – 10) region were replaced with 288 
the GGGS × 2 linker sequence (Fig. 6A and B). We observed significant reduction in 289 
expression of mut1 compared to WT in cells. These observations, together with the 290 
results shown in Fig. 5G, supported the suggestion that the specific sequence of amino 291 
acids 3 – 10 in LASV Z is important for protein expression or stability. To narrow down 292 
the region important for LASV Z-mediated VLP production in LASV Z 3 – 10, two 293 
other mutants were constructed and VLP production was examined (Fig. 6C). Both 294 
mutants exhibited less cellular expression and showed lower VLP production ratios than 295 
WT. These results indicated that both the sequences of amino acids 3 – 6 and 7 – 10 296 
have some roles, but are not critical, for cellular expression or stability as well as VLP 297 
production. The reason for stable expression of the whole deletion LASV Z 3 – 10 (∆1) 298 
is not clear. Finally, to identify the specific amino acid that regulates VLP production 299 
with the region of amino acids 3 – 10 in LASV Z, single amino acid mutations were 300 
introduced, and VLP assays were performed (Fig. 6B). In addition, double lysine 301 
mutations (K4, 7A) were also examined for VLP production efficiency (Fig. 6C). None 302 
of the single or double mutation constructs showed reduction of VLP production, 303 
indicating that these single or double mutations were not sufficient for determining the 304 
amino acids responsible for VLP production in the ∆1 region. All arenaviral Z and 305 
several retroviral Gag proteins have been reported to be myristoylated at G2 for 306 
attachment to the cellular membrane (Bryant & Ratner, 1990; Gottlinger et al., 1989; 307 
Pal et al., 1990; Urata & Yasuda, 2012; Urata et al., 2009), and this attachment is 308 
critical for the assembly and production of infectious progeny virions. To produce Lassa 309 
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VLP, the 3 – 10 amino acid sequence does not have to be specific for LASV Z, as 310 
substitution of this region with HIV-1 Gag and RSV v-src recovered the defect of ∆1 311 
VLP production, although the degree of recovery did not completely reach the WT level 312 
(Fig. 5G). The ratios of VLP production induced by mut2 and mut3 were reduced 313 
compared to WT. These results suggested that a specific amino acid of LASV Z 3-10 is 314 
required to produce VLP efficiently. Based on these results, we concluded that the 315 
whole region of amino acids 3 – 10 in LASV Z is critical for myristoylation and is 316 
important for efficient protein expression, stability, and subsequent VLP production. 317 
In conclusion, we described several important aspects of the molecular mechanisms of 318 
LASV Z and Z+GPC-mediated VLP production. As Z plays a central role in arenavirus 319 
assembly and budding, these findings will contribute to our understanding of LASV 320 




Plasmids, siRNAs, and antibodies. The expression plasmids for Lassa virus Z 323 
(pCLV-Z) and GPC (pCLV-GPC) (both Josiah strain) were generated previously 324 
(Sakuma et al., 2009; Urata et al., 2006). pCLV-Z-FLAG and pCLV-GPC-FLAG, which 325 
express Z and GPC with FLAG-tags at their C-termini, were also constructed by 326 
insertion of FLAG-tag sequence into pCLV-Z and pCLV-GPC, respectively. The NP 327 
gene of Josiah strain was cloned into pcDNA3.1 (–) (Invitrogen, Carlsbad, CA) and the 328 
HA-tag was fused to its C-terminus (pCLV-NP-HA). The expression plasmids for Z 329 
mutants were constructed with a QuikChange® Site-Directed Mutagenesis Kit 330 
(Stratagene, La Jolla, CA) or KOD Plus Mutagenesis Kit (Toyobo, Osaka, Japan) 331 
according to the respective manufacturer’s instructions. Human immunodeficiency virus 332 
1 (HIV-1) gag and Rous sarcoma virus (RSV) v-src genes were referenced from 333 
GenBank accession numbers AF324493.2 and K01644.1, respectively. Polyclonal 334 
antibodies against LASV Z or GPC/GP2 were described previously (Sakuma et al., 335 
2009; Urata et al., 2006). Anti-HA (#2367, 6E2) and Streptavidin-HRP (#3999) were 336 
purchased from Cell Signaling Technology, Inc. (Danvers, MA). Anti-FLAG M2 337 
antibody to detect pCLV-GPC-FLAG on Western blotting was purchased from Sigma 338 
(St. Louis, MO). Anti-CD63 antibody was obtained from Santa Cruz (sc-5275; Santa 339 
Cruz Biotechnology, Santa Cruz, CA). siRNA and antibody against Tsg101 were 340 
described previously (Garrus et al., 2001; Urata et al., 2006). Second antibodies against 341 
rabbit-IgG (W401B) and mouse IgG (A2304), both conjugated with peroxidase, were 342 
purchased from Promega (Madison, WI) and Sigma, respectively. The signals were 343 
detected using ECL Prime Western Blotting Detection Reagents (GE Healthcare, 344 
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Waukesha, WI) according to the manufacturer’s instructions. 345 
Cells and MβCD treatment. 293T, Huh-7, MDCK, and Vero cell lines were 346 
maintained with Dulbecco’s modified Eagle’s medium (DMEM) (D6429; Sigma) 347 
containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (Life 348 
Technologies, Carlsbad, CA). Cells were treated with MβCD (C4555; Sigma, 8.7 mM 349 
as a final concentration) for 30 minutes to chelate cellular cholesterol, and culture media 350 
were replaced with fresh media before application of the transfection mixture.  351 
VLP assay. Detection of LASV Z-mediated VLP production was described previously 352 
(Urata et al., 2006). Briefly, 293T cells were transfected with pCLV Z (or mutants) and 353 
related plasmids with Trans-IT LT-1 (Mirus Bio Corp., Madison, WI). At 48 hours 354 
posttransfection, cell debris was removed by centrifugation, and media were loaded on 355 
top of a 20% sucrose cushion, followed by ultracentrifugation (195000 × g, 30 minutes, 356 
4°C) to collect VLPs. Cells were lysed with lysis A buffer (1% Triton X-100, 25 mM 357 
Tris-HCl, pH 8.0, 50 mM NaCl, and 10% Na-deoxycholate), and cell debris was 358 
removed by centrifugation (13000 × g, 10 minutes, 4°C). VLPs and cell lysate samples 359 
were separated by SDS-PAGE followed by Western blotting. Transfection of Huh-7, 360 
MDCK, and Vero cells was performed with Lipofectamine 2000 (Invitrogen), and at 6 361 
hours posttransfection, media were replaced with fresh media. Relative VLP production 362 
was calculated as total VLP-associated Z/cell-associated Z and normalized to wild-type 363 
(WT) or control treatment as 1.0. 364 
Immunofluorescence microscopy. At 24 hours after transfection with pCLV-Z-FLAG 365 
and/or pCLV-GPC, 293T cells were fixed with 4% paraformaldehyde (Wako, Osaka, 366 
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Japan) for 30 minutes at room temperature (RT). Fixed cells were treated with blocking 367 
buffer [10% FBS diluted with dilution buffer consisting of 3% BSA+0.3% Triton-X100 368 
in PBS (–)] for 1 hour. After blocking, monoclonal antibody against FLAG tag (M2; 369 
Sigma) and/or polyclonal antibody against LASV GPC/GP2, as well as Vybrant 370 
component A (V-34404, Vybrant Lipid Raft labeling kit 555; Life Technologies), were 371 
used to stain LASV Z, GPC/GP2, and lipid rafts (GM1), respectively. After 2 hours of 372 
incubation at RT for the 1st staining, cells were washed twice with PBS (–), and goat 373 
anti-mouse IgG FITC (ab7064; Abcam) or goat anti-rabbit IgG Alexa Fluor 647 374 
(ab150079; Abcam) was used for labeling the 1st antibodies for 2 hours at RT. After the 375 
2nd staining, cells were washed twice with PBS (–), and DAPI was used to stain the 376 
nuclei for 30 minutes at RT. Finally, after three washes with PBS (–), cells were 377 
incubated with Vybrant component B for 15 minutes at 4°C to crosslink the cholera 378 
toxin subunit B (CT-B)-labeled lipid rafts (Vybrant component A) with anti-CT-B 379 
antibody (Vybrant component B), and then washed three times with PBS(–), covered 380 
with slide glasses, and observed by confocal microscopy (LSM780; Zeiss, Oberkochen, 381 
Germany). In the CD63 localization experiment, LASV Z and mutants were detected by 382 
anti-LASV Z polyclonal antibody, and CD63 was detected by anti-CD63 monoclonal 383 
antibody. Goat anti-mouse IgG FITC (ab7064; Abcam) or goat anti-rabbit IgG TRITC 384 
(T5268; Sigma) was used as the respective second antibody. 385 
Detection of myristoylated protein. Click-iT myristic acid azide (C10268; Invitrogen), 386 
biotin alkyne (B10185; Invitrogen), and Click-iT protein reaction buffer kit (C10276; 387 
Invitrogen) were used to detect LASV Z myristoylation according to the manufacturer’s 388 
instructions. Briefly, 293T cells (1×106 cells) were seeded and incubated for 6 hours 389 
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under 5% CO2 at 37°C. After incubation, cells were transfected with 0.5 µg of plasmids 390 
using LT-1 and then cultured for a further 18 hours. Culture media were replaced with 391 
fresh media containing click-iT myristic acid azide at a final concentration of 10 µM. 392 
After 6 hours of incubation, cells were lysed with lysis buffer (50mM Tris-HCl, pH 8.0, 393 
1% SDS) containing protease inhibitor (80-6501-23; GE Healthcare) and benzonase 394 
(E1014; Sigma). After centrifugation (1300 × g, 5 minutes, 4°C) to remove cell debris, 395 
samples were used for click reaction using biotin alkyne, and methanol/chloroform 396 
protein precipitation was performed to prepare the samples for SDS-PAGE. Samples of 397 
the same volume were loaded and detected by Western blotting with either rabbit 398 
anti-LASV Z polyclonal antibody followed by HRP anti-rabbit IgG to detect LASV Z 399 
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FIGURE LEGENDS 525 
Figure 1. Trans factors that affect Lassa VLP production. (A) Effects of GPC and 526 
NP on LASV Z-mediated VLP release. 293T cells were transfected with pCLV-Z alone 527 
or with a combination of pCLV-GPC and/or pCLV-NP-HA. The empty vector, pCAGGS, 528 
was transfected to adjust the total amount of plasmid. At 48 hours posttransfection, 529 
culture supernatants were collected, and VLPs were collected by ultracentrifugation as 530 
described previously (Urata et al., 2006). Cell lysates were prepared with Lysis A buffer. 531 
Cell lysates and VLPs were subjected to SDS-PAGE, followed by Western blotting 532 
using polyclonal antibodies against LASV-Z, LASV GP2, as well as HA to detect 533 
LASV NP (Left). The intensities of the bands were quantified by LAS3000 (Fujifilm, 534 
Tokyo, Japan). The efficiencies of VLP production were calculated as VLP-associated 535 
Z/Cell-associated Z. The efficiency of LASV Z alone was set to 1.0 and relative VLP 536 
production is shown in the right panel. The data are averages and standard deviations 537 
from three independent experiments. (B and C) The involvement of cholesterol in Lassa 538 
VLP production in several cell lines. 293T cells (B), Huh-7 cells, and Vero cells (C) 539 
were pretreated with either DMSO or MβCD (8.7 mM) for 30 minutes, washed once 540 
with PBS (–), followed by transfection with pCLV-Z and pCAGGS (empty vector) or 541 
pCLV-Z and pCLV-GPC. In the case of MDCK cells, pCLV-GPC-FLAG was 542 
transfected instead of pCLV-GPC. At 48 hours posttransfection, VLP and cell lysates 543 
were analyzed as described above.  544 
Figure 2. LASV Z and GPC/GP2 do not colocalize at lipid rafts. 293T cells were 545 
cultured on poly-L-lysine-coated cover glasses, and transfected with pCLV-Z-FLAG (A), 546 
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pCLV-GPC (B), or both pCLV-Z-FLAG and pCLV-GPC (C – E). All samples were fixed 547 
24 hours posttransfection. Z-FLAG was detected by mouse anti-FLAG monoclonal 548 
antibody followed by anti-mouse IgG-FITC antibody; GPC/GP2 was detected by rabbit 549 
anti-GPC/GP2 polyclonal antibody followed by anti-rabbit IgG-Alexa Fluor 647 550 
antibody. Lipid rafts were stained with a Vybrant Lipid Raft labeling kit 555, and nuclei 551 
were stained with DAPI. Z stack was also captured. In (C), the dotted square shows a 552 
higher magnification view of the bottom right. The white arrow indicates the 553 
colocalization of LASV Z and GPC/GP2 (C and D). 554 
Figure 3. LASV GPC increases the colocalization of Z with CD63. A. LASV Z-FLAG 555 
was expressed in 293T cells, and LASV Z and CD63 were stained. B. LASV Z-FLAG 556 
and LASV GPC were coexpressed in 293T cells, and LASV Z and CD63 were stained. 557 
Nuclei were stained with DAPI. Bar, 5 µm. C. Cell number of LASV Z and CD63 558 
colocalized cells were divided by LASV Z-positive cell number (100 cells) in both 559 
LASV Z alone and LASV Z+GPC expressing samples, and indicated with percent (%) 560 
in y-axis.  561 
Figure 4. The involvement of Tsg101 and L-domains in Lassa VLP production. (A) 562 
293T cells were transfected with scramble siRNA (siCont) or siRNA targeting Tsg101 563 
(siTsg101). At 24 hours posttransfection, culture media were replaced with fresh media 564 
and cells were transfected with each siRNA and both pCLV-Z and pCLV-GPC. VLP 565 
production was analyzed as described above (Fig. 1A) (Left). The efficiency of VLP 566 
production was calculated as described in Fig. 1A and the results are shown on the right. 567 
(B) 293T cells were transfected with pCLV-Z (WT), pCLV-Z-AAAP (PTAP>AAAP), or 568 
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pCLV-Z-PPPA (PPPY>PPPA), together with pCLV-GPC. VLP production was analyzed 569 
as described in Fig. 1A (Left). The efficiency of VLP production was also calculated as 570 
described in Fig. 1A (Right). The data are averages and standard deviations from three 571 
independent experiments. 572 
Figure 5. Cis factors that affect Lassa VLP production. (A) Schematic representation 573 
of LASV Z deletion mutants used in this study. Two L-domains (PTAP and PPPY) are 574 
shown at the top. (B) 293T cells were transfected with pCLV-Z (WT) or the expression 575 
plasmid for each LASV-Z deletion mutant. VLP production was analyzed as described 576 
in Fig. 1A. (C) The efficiencies of VLP production of each Z mutant were calculated as 577 
described in Fig. 1A. The efficiency of WT was set to 1.0. The data are averages and 578 
standard deviations from three independent experiments. (D) Effects of GPC expression 579 
on VLP production mediated by ∆1. 293T cells were transfected with pCLV-Z or 580 
pCLV-Z∆1 together with pCLV-GPC. VLP production was analyzed as described in Fig. 581 
1A. (E) Myristoylation of ∆1. 293T cells were transfected with empty plasmid, pCLV-Z, 582 
pCLV-Z ∆1, or pCLV-ZG2A. At 18 hours posttransfection, culture media were replaced 583 
with fresh media containing Click-iT myristic acid azide (10 µM). At 6 hours after 584 
medium exchange, cell lysates were prepared and used to perform click reaction with 585 
biotin alkyne according to the manufacturer’s instructions. Purified proteins were 586 
detected with either rabbit anti-LASV Z polyclonal antibody followed by 587 
HRP-conjugated anti-rabbit IgG antibody or HRP-conjugated Streptavidin. (F) 588 
Schematic representation of HIV-1 Gag10 and RSV v-src10. LASV Z 3 – 10 amino acid 589 
sequence was replaced with the 3 – 10 sequence of HIV-1 Gag or v-src. The asterisk (*) 590 
indicates the consensus myristoylation amino acid (Ser) at position 6. (G) 293T cells 591 
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were transfected with pCLV-Z (WT) or pHIV-1 Gag10 LASV Z (HIV-1 Gag10) of 592 
pv-src10 LASV Z (v-src10). VLP production was analyzed as described in Fig. 1A. (H) 593 
LASV-Z (WT), HIV-1 Gag10, and v-src10 were expressed in 293T cells, and stained 594 
together with CD63. Nuclei were stained with DAPI. Bar, 5 µm. 595 
 596 
Figure 6. Analysis of VLP production in LASV Z 3 – 10 amino acid mutants. (A) 597 
Alignment of the N-terminal amino acid sequences of Z from three LASV strains 598 
(Josiah strain, NP_694871.1, NL strain, AAO59510, CSF strain, AAO59514.1), three 599 
LASV Z mutants (mut1, mut2, and mut3) and the conserved N-myristoylation motif. 600 
The amino acid sequences of positions 1 – 10 are indicated. (B) Cellular expression of 601 
mut1. Either WT or mut1 was expressed in 293T cells, and cellular expression was 602 
examined by Western blotting. (C) VLP assay was performed to examine the efficiency 603 
of mut2 and mut3 for VLP production in 293T. The levels of VLP production of each 604 
single point mutant (D) or double lysine mutant (E) of LASV Z were analyzed as 605 
described in Fig. 1A. 606 
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